Xtant Medical Holdings Inc (XTNT, Financial) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $29.30 million, and the earnings are expected to come in at -$0.03 per share. The full year 2024's revenue is expected to be $118 million, and the earnings are expected to be -$0.10 per share. More detailed estimate data can be found on the Forecast page.
Xtant Medical Holdings Inc (XTNT, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Xtant Medical Holdings Inc (XTNT) have been adjusted from $118.40 million to $118 million for the full year 2024, and from $134.45 million to $134.10 million for 2025. Similarly, earnings estimates have been revised from -$0.09 per share to -$0.10 per share for the full year 2024, and from -$0.01 per share to -$0.04 per share for 2025.
Xtant Medical Holdings Inc (XTNT, Financial) Reported History
In the previous quarter of June 30, 2024, Xtant Medical Holdings Inc's (XTNT) actual revenue was $29.94 million, which beat analysts' revenue expectations of $28.70 million by 4.33%. Xtant Medical Holdings Inc's (XTNT) actual earnings were -$0.03 per share, which missed analysts' earnings expectations of -$0.02 per share by 50%. After releasing the results, Xtant Medical Holdings Inc (XTNT) was up by 0.26% in one day.
Xtant Medical Holdings Inc (XTNT, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 2 analysts, the average target price for Xtant Medical Holdings Inc (XTNT) is $2.25 with a high estimate of $3 and a low estimate of $1.50. The average target implies an upside of 328.16% from the current price of $0.53.
Based on GuruFocus estimates, the estimated GF Value for Xtant Medical Holdings Inc (XTNT, Financial) in one year is $1.05, suggesting an upside of 99.81% from the current price of $0.5255.
Based on the consensus recommendation from 2 brokerage firms, Xtant Medical Holdings Inc's (XTNT, Financial) average brokerage recommendation is currently 1.5, indicating a "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
